

In the Claims:

No claims were amended herein. The claims and their status are shown below.

1. (Previously presented) A method for reducing A β -induced inflammation in a patient in need of such treatment comprising administering an effective amount of a pharmaceutical composition comprising a protein with the amino acid sequence of SEQ ID NO:1, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier therefor.
2. (Original) A method according to claim 1, wherein the carrier is aqueous.
3. (Original) A method according to claim 1, wherein the composition further comprises an cholinesterase inhibitor.
4. (Original) A method according to claim 3, wherein the cholinesterase inhibitor is selected from the group consisting of ambenonium, adrophonium, methylphysostigmine, neostigmine, pyridostigmine, and pharmaceutically acceptable salts thereof.
5. (Original) A method according to claim 3, wherein the cholinesterase inhibitor is an acetylcholinesterase inhibitor.
6. (Original) A method according to claim 5, wherein the acetylcholinesterase inhibitor is selected from the group consisting of tacrine, galanthamine, and pharmaceutically acceptable salts thereof.
- 7-18. (Canceled)